Aktis Oncology, Inc. Common stock
NASDAQ: AKTS · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Aktis Oncology, Inc. Common stock (AKTS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $254834.00 | $16964.00 | $1.21M | $1.44M | $1.79M | $15.35M | $0.00 | $27.12M | $1.49M | $6.50M |
| Revenue growth (YoY) | — | — | -93.3% | +7020.2% | +19.5% | +24.0% | +757.5% | -100.0% | — | -94.5% | +336.9% |
| Cost of revenue | — | $28749.00 | $110084.00 | $1.02M | $1.01M | $2.41M | $19.49M | — | $30.24M | $28.07M | — |
| Gross profit | — | $226085.00 | $-93120.00 | $188375.00 | $430000.00 | $-624000.00 | $-4.14M | — | $-3.12M | $1.49M | $6.50M |
| Gross margin | — | 88.7% | -548.9% | 15.6% | 29.8% | -34.9% | -27.0% | — | -11.5% | 100.0% | 100.0% |
| R&D | $470987.00 | $1.76M | $4.43M | $13.27M | $19.25M | $20.52M | $35.71M | $14.30M | $25.92M | $40.95M | $67.45M |
| SG&A | $920031.00 | $2.94M | $6.02M | $8.80M | $8.70M | $10.89M | $20.71M | $5.11M | $7.68M | $11.31M | $12.60M |
| Operating income | $-1.39M | $-4.69M | $-9.96M | $-22.28M | $-27.52M | $-32.04M | $-60.55M | $-19.76M | $-34.79M | $-52.05M | $-74.68M |
| Operating margin | — | -1842.0% | -58704.1% | -1844.4% | -1906.9% | -1789.8% | -394.5% | — | -128.3% | -3500.3% | -1149.5% |
| EBITDA | $-629596.00 | $-3.87M | $-10.57M | $-20.62M | $-25.07M | $-28.96M | $-52.83M | $-17.48M | $-27.45M | $-42.41M | $-61.40M |
| EBITDA margin | — | -1518.6% | -62329.0% | -1707.1% | -1737.4% | -1617.8% | -344.1% | — | -101.2% | -2851.7% | -945.1% |
| EBIT | $-639236.00 | $-3.90M | $-10.68M | $-21.88M | $-27.57M | $-32.15M | $-60.95M | $-17.93M | $-28.64M | $-43.98M | $-63.73M |
| Interest expense | — | — | — | $329422.00 | $2.89M | $4.57M | $77000.00 | — | $2.32M | $2.66M | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.22M | $-5.41M | $-9.11M | $-21.74M | $-30.88M | $-40.87M | $-59.19M | $-17.93M | $-28.64M | $-43.98M | $-63.73M |
| Net income growth (YoY) | — | -342.5% | -68.5% | -138.7% | -42.0% | -32.3% | -44.8% | +69.7% | -59.7% | -53.6% | -44.9% |
| Profit margin | — | -2121.4% | -53691.6% | -1799.8% | -2139.9% | -2283.1% | -385.6% | — | -105.6% | -2957.6% | -980.9% |
Frequently asked questions
What is Aktis Oncology, Inc. Common stock's revenue?
Aktis Oncology, Inc. Common stock's trailing twelve-month revenue is $8.28M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is AKTS?
In its most recent fiscal year, AKTS ran a gross margin of 100.00%, an operating margin of -1,149.52%, and a net margin of -980.93%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does AKTS generate?
AKTS produced $-73.71M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is AKTS's balance sheet healthy?
AKTS holds $37.78M in cash and equivalents against — in long-term debt, on $-146.15M of shareholder equity. That debt is best read against the cash flow the business throws off each year.